key: cord-0799799-9npdijef authors: Kanjanapan, Yada; Blinman, Prunella; Underhill, Craig; Karikios, Deme; Segelov, Eva; Yip, Desmond title: Medical Oncology Group of Australia position statement: COVID‐19 vaccination in patients with solid tumours date: 2021-06-21 journal: Intern Med J DOI: 10.1111/imj.15339 sha: a9e7502dc343f10a325a16e0b123988adb5ec2f6 doc_id: 799799 cord_uid: 9npdijef People with cancer are vulnerable to increased morbidity and mortality from the coronavirus disease 2019 (COVID‐19). COVID‐19 vaccination is key to protecting the population of people with cancer from adverse outcomes of SARS‐CoV‐2 infection. The Medical Oncology Group of Australia aimed to address the considerations around COVID‐19 vaccination in people with cancer, in particular, safety and efficacy of vaccination. The assessment of patients with generalised allergic reaction to anti‐cancer therapy containing vaccine components and practical implementation of vaccination of people on active anti‐cancer therapy are also discussed. The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality worldwide. People with cancer are at greater risk of serious complications and death from SARS-CoV-2 infection. 1,2 People with cancer have high case-fatality rates from COVID-19 with reported rates of 21-25% from the United States and United Kingdom, 3,4 compared with 1-4% in the general population. 3 People with cancer comprise a heterogeneous population at different points of the cancer disease trajectory. There are differences in patients' age, comorbidities, tumour types and the type of systemic anti-cancer therapy. These factors all contribute towards an individual's risk of COVID-19 infection and related complications, with potential implications in their response to vaccination. While Australian guidelines on COVID-19 exist for haematological malignancies 5 and haematological stem cell transplant and chimeric antigen receptor T-cell (CAR-T cell) therapy recipients, 6 people with solid tumours are, by comparison, generally less immunocompromised from their treatment and underlying cancer. This position statement discusses key issues relevant to COVID-19 vaccination for people with solid tumours in the Australian context. Representative members from the Medical Oncology Group of Australia (MOGA) convened a working group to produce this position statement. Key questions relevant to the solid tumour population were identified. The authors reviewed the existing literature in order to address these questions using the available evidence of Is the vaccine safe for people with cancer? People with cancer were under-represented in COVID-19 vaccine clinical trials. [7] [8] [9] Even in the phase III trial of the BNT162b2 (Pfizer) vaccine, in which 1395 people (3.7% of study population) with a history of malignancy were included (and 733 (3.9%) received the vaccine), people with active malignancy receiving systemic immunosuppressive therapy were excluded. 8 The safety profile of COVID-19 vaccines to date have been favourable, [7] [8] [9] and while cases of anaphylaxis were observed, these were rare events, with vaccination safe for the majority of the general population. While specific evidence regarding COVID-19 vaccines in people with cancer is limited, there is no scientific rationale for a heightened risk of vaccine-related toxicities. Concerns have been raised about the active constituents of the Pfizer and Moderna mRNA vaccines (polyethylene glycol (PEG)); and AstraZeneca and Johnson & Johnson vaccines (polysorbate 80), which are active components of many anti-cancer therapies and have been implicated in allergic reactions. 10 The Australasian Society of Clinical Immunology and Allergy (ASCIA) has advised people with cancer and a history of generalised allergic reaction to anti-cancer agents containing polysorbate (e.g. docetaxel) or polyoxyl 35 castor oil (e.g. paclitaxel) remain eligible for vaccination in a medical facility with capability to manage anaphylaxis and a lengthened (30 min) postvaccination observation period. 11 Patients with a history of generalised allergic reaction and/or anaphylaxis to pegylated liposomal doxorubicin or pegfilgrastim should be referred to an immunologist for COVID-19 vaccination, due to high risk of cross-reactivity with the Pfizer vaccine. Patients with a history of multiple drug allergies (where PEG or polysorbate 80 is present in the allergenic drugs) should also have a review or discussion by an immunologist prior to COVID-19 vaccination to consider skin prick testing and assess the risk/benefit of vaccination for each patient. Vaccination is contraindicated with documented anaphylaxis to one of the COVID-19 vaccine components (Pfizer-PEG or AstraZeneca-polysorbate 80). These patients may still be able to receive a different COVID-19 vaccine not containing the allergenic component. Any serious or unexpected reaction to COVID-19 vaccination should be reported to the Therapeutics Goods Administration (TGA) in Australia. Live vaccines are contraindicated for immunocompromised patients including those receiving cytotoxic therapy. Of the two TGA-approved (Pfizer BNT162b2 (mRNA) and AstraZeneca AZD1222 (viral vector)) vaccines, neither are live vaccines. Is there a priority ranking for COVID-19 vaccination? People with cancer who are immunosuppressed from anti-cancer therapy should be prioritised for vaccinations, due to their risk of an adverse outcome from COVID-19 infection. 2 Additionally, risk factors for cancer overlap with many risk factors for adverse outcome from COVID-19, including increased age or comorbidities such as chronic pulmonary disease. Among people with cancer, risk factors for increased risk of complications from COVID-19 infection are listed below, with the odds ratio (OR) for 30-day mortality: 12 13 Chemotherapy was also not significantly associated with 30-day all-cause mortality in cancer patients with COVID-19 infection in the COVID-19 and Cancer Consortium (CCC19) cohort study of 1035 patients from the United States, Canada and Spain. 12 The contrasting findings from these studies means the impact of chemotherapy on outcome from COVID-19 infection remains uncertain. In the Australian context, with minimal local COVID-19 transmission, interruption of chemotherapy is not generally recommended. This remains a clinical benefit/risk assessment by clinicians for their patients, taking into consideration the local epidemiology of COVID-19 at the time, given that the risk of adverse COVID-19 outcomes from chemotherapy is not established. Are there specific considerations for immunotherapy? Immune checkpoint inhibitor treatment was not associated with adverse outcome from COVID-19 infection in the majority of studies. 14, 15 There are currently no published data on the immunogenicity of COVID-19 vaccination among recipients of immunotherapy. However, studies support the efficacy of influenza vaccination among checkpoint therapy recipients. 16 Will the COVID-19 vaccination be effective in people with cancer and for how long? People with cancer on cytotoxic chemotherapy are immunosuppressed and may mount an inferior immune response from vaccination. 17 Lower immunogenicity from influenza vaccination, as measured by seroconversion rate and magnitude of antibody response, has been shown in people with cancer on chemotherapy compared with the general population. 17 Published rates of clinical effectiveness of COVID-19 vaccines are 95% with Pfizer, 8 and ideally away from the nadir period. 20 This is due to the expectation that blood count recovery would parallel improved immune function and potentially greater immune response from vaccination. Ultimately, the optimal timing of COVID-19 vaccination in patients undergoing chemotherapy remains uncertain, with some guidelines recommending administration of the vaccine as soon as available and practical to do so. 21 As COVID-19 vaccination side-effects such as fever are expected at 2-3 days post-vaccination with potential intensification of side-effects following the second dose, systemic anticancer therapy should be avoided at this time. As of 20 February 2021, two vaccines are approved by the Australian TGA: Pfizer/BioNTech BNT162b2 and AstraZeneca AZD1222 vaccines. Both vaccines require administration of two doses, 21 days apart for the Pfizer vaccine and 12 weeks apart for the AstraZeneca vaccine. 22 In people due to commence anti-cancer therapy, both doses should ideally be completed at least 2 weeks prior to starting treatment. 20 The commencement of anti-cancer therapy should not be delayed for COVID-19 vaccination. What is the impact of vaccination status on cancer care delivery? Government national roll-out strategy. The impact of non-vaccinated individuals (due to contraindications or personal choice) on healthcare delivery currently remains uncertain. Of particular relevance to oncology, the delivery of anti-cancer therapy in open plan infusion centres may need to take into consideration the vaccination status of patients and healthcare workers. Clinicians need to make individual patient risk-benefit assessment regarding COVID-19 vaccination, and should address any vaccine hesitancy in people with cancer using scientific evidence. People with cancer are at an increased risk for adverse outcomes from SARS-CoV-2 infection. COVID-19 vaccination is key to protecting this vulnerable population. This MOGA position statement outlines evidence supporting COVID-19 vaccination in people with cancer, including those on anti-cancer therapy such as chemotherapy and immunotherapy. It considers vaccinations of people with generalised allergic reaction to anti-cancer therapy containing vaccine components who may require additional precautions in COVID-19 vaccination. The statement aims to assist cancer clinicians in their individual patient decision-making regarding COVID-19 vaccination. It is intended as a resource for all healthcare professionals caring for people with cancer to facilitate discussion around and encourage uptake of COVID-19 vaccination (Boxes 1,2). Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited Case fatality rate of cancer patients with COVID-19 in a New York hospital system Factors affecting COVID-19 outcomes in cancer patients: a first report from Guy's COVID-19 Vaccination in Haematology Patients: An Australia and New Zealand Consensus Position Statement Zealand Transplant and Cellular Therapies. COVID19 Vaccination Consensus Position Statement FINAL-ANZTCT-COVID19-Vaccination-Position-Statement Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine affected-cancer/covid-19-and-cancer/covid-19-vaccinesand-cancer/FAQs Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach Autoimmunity and COVID-10 Vaccination Position Statement Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Chemotherapy and COVID-19 outcomes in patients with cancer COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of Its Phase 3 ENSEMBLE Trial -MSK-COVID19-VACCINE-GUIDELINES.pdf 21 National Comprehensive Cancer Network. Preliminary Recommendations of the NCCN COVID-19 Vaccination Advisory Committee Therapeutics Goods Administration